N-Pyrrolidino Protonitazene (Protonitazepyne): Complete Toxicology, Deaths & Safety Monograph

N-Pyrrolidino Protonitazene (Protonitazepyne): Complete Toxicology, Deaths & Safety Monograph

Emergency opioid warning: If someone cannot be awakened, has slow/irregular/stopped breathing, blue or gray lips/skin, gurgling/choking, or collapses after an unknown opioid/powder/vape, call emergency services and give naloxone if available. Do not wait for exact nitazene identification.

Quick answer

N-pyrrolidino protonitazene (protonitazepyne, NPP) is a very potent nitazene synthetic opioid with direct human overdose and fatality evidence.

It first appeared in U.S. forensic surveillance in 2023.

The evidence has changed rapidly since then:

• CFSRE identified toxicology cases and drug material;
• severe poisonings have been clinically analyzed;
• human metabolic pathways are now characterized;
• Norway recorded protonitazepyne deaths;
• a 2026 forensic report judged it the primary cause of a fatal intoxication;
• U.S. control became permanent in 2026.

This is no longer a “theoretical new opioid.”

Identity

History and emergence

CFSRE first detected N-pyrrolidino protonitazene in the United States in January 2023.

Its rapid trajectory illustrates modern nitazene-market turnover:

1. first analytical confirmation;
2. early fatal/postmortem detections;
3. international spread;
4. WHO/CND scheduling;
5. permanent U.S. Schedule I.

UNODC reported the compound from 11 countries/territories by early 2025.

Relationship to protonitazene

Protonitazepyne and protonitazene share the propoxy-benzyl nitazene scaffold but differ in the amine-side-chain structure.

That difference materially changes receptor pharmacology.

A product labeled “protonitazene” therefore cannot be assumed to have the potency or toxicology of protonitazepyne.

This matters because a published fatality involved mislabeling between the two.

Pharmacology

Mu-opioid receptor

Modern receptor work characterizes protonitazepyne as a MOR-selective full agonist.

A 2025/2026 pharmacology study reported:

• MOR potency around 3.7 nM in the assay used;
• high efficacy;
• substantially lower potency/partial agonism at kappa and delta opioid receptors.

Fentanyl comparisons

Different assays have generated different relative-potency estimates.

Early data cited by CFSRE suggested very high potency relative to fentanyl. More recent receptor work found an approximately seven-fold difference in its assay system.

A 2026 fatality paper cites an estimated in-vitro potency around 25-fold greater than fentanyl based on other data.

The correct conclusion is:

Protonitazepyne is highly potent at MOR, but there is no single validated human fentanyl-equivalence ratio.

Assay potency must not become a consumer dose conversion.

Human severe-poisoning evidence

A 2025 report compared severe protonitazene and protonitazepyne poisonings and analyzed metabolic profiles.

The existence of clinically severe human exposure confirms that this drug's hazard is not limited to receptor models.

Clinical nitazene toxicity centers on:

• profound CNS depression;
• respiratory depression;
• unresponsiveness;
• opioid toxidrome;
• need for emergency opioid-overdose care.

Fatality evidence

2026 primary-cause fatality

A forensic report described death after vaping material containing N-pyrrolidino protonitazene.

The compound was quantified in:

• postmortem serum;
• heart blood;
• femoral blood;
• liver;
• bile;
• stomach contents;
• urine.

Other detected substances did not adequately explain the death, and the authors judged protonitazepyne the primary cause.

Norway

Norwegian national surveillance documented three protonitazepyne-positive deaths in 2024.

The median postmortem peripheral-blood concentration in those three cases was in the low ng/mL range.

Those concentrations are forensic observations—not a lethal-dose chart.

Product mislabeling: a major hazard

In the 2026 fatality, the material was reportedly labeled protonitazene but contained N-pyrrolidino protonitazene.

That matters because:

• the molecules differ;
• receptor potency differs;
• the user may assume prior experience with another nitazene applies.

A mislabeled high-potency opioid creates a direct unintended-overdose mechanism.

Metabolism

Human hepatocyte and authentic blood/urine work identified pathways including:

• nitroreduction;
• pyrrolidine N-dealkylation;
• oxidation to an N-butanoic acid derivative;
• O-dealkylation.

Biomarkers

Proposed analytical biomarkers include:

• 5-amino-protonitazepyne in blood;
• N-butanoic acid derivatives in urine.

Metabolite targets can extend or strengthen detection when parent drug is low.

Metabolite pharmacology

Docking work predicts major metabolites have much lower MOR affinity than parent protonitazepyne.

That supports the parent compound as the primary pharmacologic driver, but metabolite activity has not been comprehensively validated in humans.

Pharmacokinetics

Controlled human PK remains absent.

No clinical study establishes:

• bioavailability by route;
• half-life;
• time to peak;
• accumulation;
• clearance.

Postmortem concentrations and metabolism studies are not substitutes for controlled PK.

Acute toxicity and overdose

Expected/severe opioid effects include:

• extreme sedation;
• miosis;
• slow or stopped breathing;
• hypoxia;
• aspiration;
• bradycardia/hypotension;
• cardiac arrest;
• death.

The very high MOR potency means clinically significant exposure can occur at low measured concentrations.

Naloxone

Naloxone is appropriate for suspected protonitazepyne overdose.

The presence of naloxone in fatal/clinical investigations shows it is part of real-world emergency response.

However:

• no protonitazepyne-specific public dosing formula is established;
• repeat treatment can be necessary with potent opioids;
• emergency observation remains important;
• co-drugs can prolong impairment.

Interactions

The most concerning combinations are other CNS/respiratory depressants:

• fentanyl and other opioids;
• benzodiazepines;
• alcohol;
• gabapentinoids;
• xylazine-containing mixtures;
• sedative-hypnotics.

Stimulants do not protect against opioid respiratory arrest.

Tolerance and physical dependence

Repeated strong MOR agonism can produce:

• tolerance;
• physical dependence;
• opioid withdrawal;
• loss-of-tolerance overdose risk after abstinence.

There is no prospective protonitazepyne cohort defining how quickly those develop.

Withdrawal

A protonitazepyne-specific withdrawal timeline has not been established.

Expected opioid-type symptoms can include:

• restlessness;
• sweating/chills;
• insomnia;
• gastrointestinal symptoms;
• muscle aches;
• anxiety;
• autonomic activation;
• craving.

No self-taper schedule can be responsibly derived from current evidence.

Dependence vs opioid use disorder

Physical dependence means withdrawal follows adaptation.

Opioid use disorder is a broader behavioral syndrome involving features such as:

• craving;
• inability to cut down;
• escalating/compulsive use;
• continued use despite harm;
• interference with responsibilities.

A person can become dependent without initially knowing which nitazene is present.

Treatment and support

There is no protonitazepyne-specific addiction medication.

Clinicians can evaluate withdrawal/OUD using established opioid-care frameworks.

Evidence-based OUD medications include:

• buprenorphine;
• methadone;
• extended-release naltrexone in appropriately selected people.

This page does not provide induction or taper dosing.

U.S. resources: FindTreatment.gov and SAMHSA 1-800-662-HELP (4357).

Drug testing

Routine immunoassays

Routine opioid or fentanyl immunoassays should not be assumed to detect protonitazepyne.

Definitive methods

Detection relies on:

• LC-MS/MS;
• LC-HRMS;
• parent compound;
• metabolite biomarkers;
• updated nitazene libraries.

Because biological concentrations can be very low, analytical sensitivity is critical.

Forensic interpretation

Postmortem redistribution

The 2026 fatality showed a higher heart-to-femoral blood ratio, consistent with possible postmortem redistribution.

That means specimen site matters.

Instability

Declining concentrations over time may indicate compound instability.

Storage and analytical timing can affect measured values.

No universal fatal level

Even a well-documented primary-cause death does not establish one lethal blood concentration for every person.

Tolerance, co-drugs, sampling site and postmortem change all matter.

Special populations

No controlled safety data exist for:

• pregnancy/breastfeeding;
• adolescents;
• older adults;
• respiratory disease/sleep apnea;
• liver/kidney disease.

For an ultra-potent opioid, these gaps increase concern rather than reassure.

Legal status

International

The UN Commission on Narcotic Drugs placed N-pyrrolidino protonitazene in Schedule I of the 1961 Single Convention in March 2025; the decision entered into force in June 2025.

United States

DEA temporarily scheduled it in August 2025.

A final order permanently placed N-pyrrolidino protonitazene in Schedule I effective February 11, 2026.

Myths and misconceptions

“Protonitazepyne is just another name for protonitazene.”
False.

“It is exactly 25× fentanyl in humans.”
No. Relative potency depends on the in-vitro assay and cannot be converted into a human dose ratio.

“Low ng/mL concentrations mean low risk.”
False. Highly potent opioids can be clinically important at very low measured concentrations.

“Naloxone cannot work on nitazenes.”
False. Naloxone remains the appropriate opioid antagonist in suspected overdose.

“One fatal blood concentration tells me the lethal threshold.”
False.

Evidence ledger

Related evidence

• Nitazene opioid family
• Protonitazene
• N-Desethyl Protonitazene
• Isotonitazene
• Metonitazene
• Substance Use, Dependence & Harm Reduction hub

Bottom line

N-pyrrolidino protonitazene has crossed from early-warning chemistry into a documented human-fatality opioid.

Its key risks are unusually clear: very high MOR potency, respiratory arrest, low-concentration forensic detection, product mislabeling, and rapidly evolving drug-market exposure.

The evidence still does not support a human fentanyl-equivalence or dose chart—and that uncertainty is part of the hazard, not a reason to minimize it.